A Phase I/IIa Study of CreaVax-HCC (Autologous Mature Dendritic Cells) to evaluate Safety and Efficacy in Patients with Hepatocellular carcinoma in TNM I to IIIC Stage after hepatic resection and/or other treatments (PEI, RFA, TACE)

Next Previous
Trial Profile

A Phase I/IIa Study of CreaVax-HCC (Autologous Mature Dendritic Cells) to evaluate Safety and Efficacy in Patients with Hepatocellular carcinoma in TNM I to IIIC Stage after hepatic resection and/or other treatments (PEI, RFA, TACE)

Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Sep 2016

At a glance

  • Drugs Liver cancer vaccine (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 11 Jun 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top